Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

What Was Tested

Researchers studied Semaglutide and Bimagrumab in this randomized controlled trial publication.

An open-label treatment extension to week 72 followed.

Randomization was stratified by sex across the treatment groups.

Who Took Part

According to the abstract, 507 adults were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Nothing was hidden in this open-label Semaglutide study: the adults and staff both knew the treatment.

Some adults received a placebo instead of Semaglutide, giving a reference point.

The timeline in the abstract includes 48 weeks.

What Was Measured

The primary and secondary endpoints were absolute change from baseline in body weight at week 48 and week 72, respectively.

The subject headings attached to it are Semaglutide, Glucagon-Like Peptides, Obesity, Antibodies, Monoclonal, Humanized and Antibodies, Monoclonal.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Semaglutide and Bimagrumab in 507 adults over 48 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2026 (Nature medicine), a journal based in United States.

More context: the Semaglutide compound page and the Bimagrumab compound page, all human trials.